Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir
- PMID: 36461940
- PMCID: PMC10132762
- DOI: 10.1093/infdis/jiac477
Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir
Abstract
Molnupiravir is an antiviral agent recently used for treating coronavirus disease 2019 (COVID-19). Here, we demonstrate that N4-hydroxycytidine (NHC), a molnupiravir metabolite, treated with cytidine deaminase (CDA) induced Cu(II)-mediated oxidative DNA damage in isolated DNA. A colorimetric assay revealed hydroxylamine generation from CDA-treated NHC. The site specificity of DNA damage also suggested involvement of hydroxylamine in the damage. Furthermore, Cu(I) and H2O2 play an important role in the DNA damage. We propose oxidative DNA damage via CDA-mediated metabolism as a possible mutagenic mechanism of NHC, highlighting the need for careful risk assessment of molnupiravir use in therapies for viral diseases, including COVID-19.
Keywords: N 4-hydroxycytidine; 8-dihydro-2′-deoxyguanosine; 8-oxo-7; DNA damage; cytidine deaminase; hydroxylamine; molnupiravir; reactive oxygen species.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Conflict of interest statement
Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Figures


References
-
- Extance A. Covid-19: what is the evidence for the antiviral molnupiravir? BMJ 2022; 377:o926. - PubMed
-
- van Schalkwyk JM. Buyer beware: molnupiravir may damage DNA. BMJ 2021; 375:n2663. - PubMed
-
- Brandsma I, Derr R, Zhang G, Moelijker N, Hendriks G, Østerlund T. Genotoxicity assessment of potentially mutagenic nucleoside analogues using ToxTracker®. Toxicol Lett 2022; 362:50–8. - PubMed